Choline C-11 API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Choline C-11 API 94793-58-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Choline C-11. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Choline C-11
- Synonyms:
- (11)C-choline , Choline C11
- Cas Number:
- 94793-58-5
- DrugBank number:
- DB09563
- Unique Ingredient Identifier:
- M4AS4XGD4Q
General Description:
Choline C-11, identified by CAS number 94793-58-5, is a notable compound with significant therapeutic applications. Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging.
Indications:
This drug is primarily indicated for: Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, imag es w ere produced with PET/CT coregistration. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Choline C-11 undergoes metabolic processing primarily in: Following intravenous administration, 11C-choline undergoes metabolism resulting in the detection of 11C- betaine as the major metabolite in blood. In a study of patients with prostate cancer or brain disorders, the fractional activities of 11C-choline and 11C- betaine in human arterial plasma appeared to reach a plateau within 25 minutes, with 11C- betaine representing 82% ± 9% of the total 11C detected at that time point. A small amount of unmetabolized 11C-choline was detected within the blood at the final sampling time point (40 minutes). This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Route of Elimination:
The elimination of Choline C-11 from the body primarily occurs through: Urinary excretion of 11C-choline was < 2% of the injected radioactivity at 1.5 hours after injection of the drug. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Choline C-11 is distributed throughout the body with a volume of distribution of: 11C-choline distributes mainly to the pancreas, kidneys, liver, spleen and colon. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Choline C-11 is a critical factor in determining its safe and effective dosage: The rate of 11C- choline excretion in urine was 0.014 mL/min. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Choline C-11 exerts its therapeutic effects through: In a study of men with prostatic hyperplasia or primary prostate cancer, PET imaging showed 11C-choline radioactivity accumulated rapidly within the prostate; uptake appeared to peak by five minutes following injection of the drug and activity was retained over the subsequent 30 minute scanning period. Little uptake was observed in the bladder and rectum. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Choline C-11 functions by: Choline C 11 Injection is a radiolabeled analog of choline, a precursor molecule essential for the biosynthesis of cell membrane phospholipids. Choline is involved in synthesis of the structural components of cell membranes, as well as modulation of trans-membrane signaling. Increased phospholipid synthesis (i.e, increased uptake of choline) has been associated with cell proliferation and the transformation process that occurs in tumor cells. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Choline C-11 belongs to the class of organic compounds known as cholines. These are organic compounds containing a N,N,N-trimethylethanolammonium cation, classified under the direct parent group Cholines. This compound is a part of the Organic compounds, falling under the Organic nitrogen compounds superclass, and categorized within the Organonitrogen compounds class, specifically within the Quaternary ammonium salts subclass.
Categories:
Choline C-11 is categorized under the following therapeutic classes: Radioactive Diagnostic Agent, Radiopharmaceutical Activity. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Choline C-11 is a type of Diagnostic agents
Diagnostic agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used in the field of medical diagnostics. These agents play a vital role in diagnosing various diseases and conditions by aiding in the visualization and identification of specific biomarkers or structures within the body.
Diagnostic agents encompass a wide range of substances, including contrast agents, radiopharmaceuticals, and imaging agents. Contrast agents are commonly used in medical imaging techniques such as X-rays, magnetic resonance imaging (MRI), and computed tomography (CT) scans. They enhance the visibility of certain tissues or organs, allowing healthcare professionals to detect abnormalities more accurately.
Radiopharmaceuticals are another type of diagnostic agent that combines a radioactive component with a pharmaceutical compound. These agents emit radiation that can be detected by specialized imaging equipment, enabling the visualization of metabolic processes and the identification of abnormal cellular activity.
Imaging agents are designed to target specific molecular structures or biomarkers within the body. They can be used to detect and visualize specific proteins, enzymes, or receptors associated with certain diseases or conditions. By targeting these specific biomarkers, imaging agents provide valuable information about the presence, location, and extent of a disease, aiding in diagnosis and treatment planning.
Overall, diagnostic agents are essential tools in modern medicine, facilitating accurate and timely diagnoses. These pharmaceutical APIs enable healthcare professionals to identify and monitor diseases at an early stage, leading to better patient outcomes and improved treatment strategies.
